menu
    • menu
    [{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Oncology","graph2":"Phase II","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Domperidone","moa":"Dopamine D2 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Sofar Spa","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Sofar Spa","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ Sofar Spa"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"1Med","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"L.Casei Dg","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sofar Spa \/ 1Med","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ 1Med"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Casei DG","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Casei DG","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei CNCM I-1572","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Sofar Spa

    Menu

    Sofar Spa

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei CNCM I-1572

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation Of The Effect Of L. Casei DG® On Vitamin D Absorption In Patients Under Vitamin D Supplementatio...

                            Details : Lactobacillus Paracasei CNCM I-1572 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Vitamin D Deficiency.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            May 27, 2022

                            Lead Product(s) : Lactobacillus Paracasei CNCM I-1572

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beclomethasone Dipropionate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once D...

                            Details : Beclomethasone Dipropionate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 05, 2021

                            Lead Product(s) : Beclomethasone Dipropionate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Domperidone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor

                            Details : Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastroesophageal Reflux.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2019

                            Lead Product(s) : Domperidone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L.Casei Dg

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : 1Med

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            L. Casei DG® in Patients With Irritable Bowel Syndrome.

                            Details : L.Casei Dg is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 28, 2018

                            Lead Product(s) : L.Casei Dg

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : 1Med

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic

                            Details : Bifidobacterium is a Microorganism drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            February 15, 2018

                            Lead Product(s) : Bifidobacterium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : German Diabetes Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of a Probiotic (Bifidobacterium in the Treatment of Infantile Colic (IC)

                            Details : Bifidobacterium is a Microorganism drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            December 09, 2016

                            Lead Product(s) : Bifidobacterium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : German Diabetes Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Casei DG

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Stu...

                            Details : Lactobacillus Casei DG is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 25, 2015

                            Lead Product(s) : Lactobacillus Casei DG

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Mo...

                            Details : Mesalazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 04, 2014

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Casei DG

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Pain...

                            Details : Lactobacillus Casei DG is a Probiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            March 04, 2014

                            Lead Product(s) : Lactobacillus Casei DG

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sofar Spa

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares

                            Details : Mesalamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diverticular Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 10, 2010

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth